<DOC>
	<DOCNO>NCT01492803</DOCNO>
	<brief_summary>This randomize placebo-controlled trial examine daily probiotic therapy lower serum LPS level immune activation among HIV-infected youth .</brief_summary>
	<brief_title>Trial Probiotics Lower Microbial Translocation Immune Activation HIV-Infected Adolescents</brief_title>
	<detailed_description>This double masked randomize placebo-controlled trial examine daily probiotic therapy lower serum lipopolysaccharide ( LPS ) level immune activation among HIV-infected youth . The study enroll two cohort : ( 1 ) cohort subject receive antiretroviral therapy ( ART ) absolute CD4 T-cell count great 350 cells/ul quantitative HIV-1 plasma RNA ( viral load ) less 50,000 copies/ml ; ( 2 ) cohort subject receive ART absolute CD4 T-cell count great 350 cells/ul quantitative HIV-1 plasma RNA ( viral load ) less 400 copies/ml .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>To consider eligible enrollment , individual must meet criterion list . Age 13 year 0 day 24 year 364 day time consent Confirmed suspect acquire HIV infection age 10 year old HIV1 infection document FDAapproved ELISA test kit confirm Western blot , HIV1 culture , HIV1 antigen , HIV1 DNA , plasma HIV1 RNA , second antibody test method ELISA time prior preentry Absolute CD4 Tcell count great 350 cells/ul preentry Cohort 1 Not receive ART exposure ART 24 week prior preentry : Quantitative HIV1 plasma RNA ( viral load ) less 50,000 copies/ml two consecutive determination least 8 week apart 24 week prior include preentry Cohort 2 Currently receive ART receive ART least 24 week prior preentry : Quantitative HIV1 plasma RNA ( viral load ) less 400 copies/ml two consecutive determination least 8 week apart 24 week prior include preentry Willingness refrain regular use foods/supplements contain probiotic supply study course study participation To consider eligible enrollment , individual must meet criterion list . Known hypersensitivity probiotic Active AIDSdefining condition acute serious illness Cohort 1 Not receive ART exposure ART 24 week prior preentry : Any quantitative HIV1 plasma RNA ( viral load ) equal great 50,000 copies/ml 24 week prior preentry . Cohort 2 Currently receive ART receive ART least 24 week prior preentry : Any quantitative HIV1 plasma RNA ( viral load ) equal great 400 copies/ml 24 week prior preentry Known history inflammatory bowel disease similar disorder GI tract Current treatment immunemodulating immunesuppressive therapy Active malignancy preentry Pregnancy Grade 3 high clinical laboratory toxicity time randomization Regular use food supplement contain probiotic within 2 week prior randomization ( see Appendix V ) Concurrent participation ATN 061 , 071 , 081 , and/or 101 protocol</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>24 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>Probiotics</keyword>
</DOC>